PTX Stock Overview
A clinical stage oncology company, develops drugs for the treatment of various cancers in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Prescient Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.042 |
| 52 Week High | AU$0.068 |
| 52 Week Low | AU$0.037 |
| Beta | 1.21 |
| 1 Month Change | 5.00% |
| 3 Month Change | 7.69% |
| 1 Year Change | -34.38% |
| 3 Year Change | -80.91% |
| 5 Year Change | -36.36% |
| Change since IPO | -99.94% |
Recent News & Updates
Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation
Jul 05
We Think Prescient Therapeutics (ASX:PTX) Can Afford To Drive Business Growth
Mar 12Recent updates
Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation
Jul 05We Think Prescient Therapeutics (ASX:PTX) Can Afford To Drive Business Growth
Mar 12We're Not Very Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Rate
Nov 14Companies Like Prescient Therapeutics (ASX:PTX) Are In A Position To Invest In Growth
Aug 01Shareholders Would Not Be Objecting To Prescient Therapeutics Limited's (ASX:PTX) CEO Compensation And Here's Why
Nov 22Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation
Oct 19Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business
Jun 19Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business
Feb 27We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Prescient Therapeutics Limited's (ASX:PTX) CEO For Now
Nov 05We Think Prescient Therapeutics (ASX:PTX) Can Easily Afford To Drive Business Growth
Aug 26Prescient Therapeutics (ASX:PTX) Is In A Good Position To Deliver On Growth Plans
May 08Does Prescient Therapeutics' (ASX:PTX) CEO Salary Compare Well With The Performance Of The Company?
Jan 11
Shareholder Returns
| PTX | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 2.4% | 1.4% | -0.6% |
| 1Y | -34.4% | 4.2% | 9.1% |
Return vs Industry: PTX underperformed the Australian Biotechs industry which returned 4.2% over the past year.
Return vs Market: PTX underperformed the Australian Market which returned 9.1% over the past year.
Price Volatility
| PTX volatility | |
|---|---|
| PTX Average Weekly Movement | 8.8% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in AU Market | 16.7% |
| 10% least volatile stocks in AU Market | 3.1% |
Stable Share Price: PTX has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: PTX's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | n/a | Steven Yatomi-Clarke | ptxtherapeutics.com |
Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-100, a first in class compound with the ability to block an cancer growth enzyme, thereby disrupting the oncogenic Ras pathway. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014.
Prescient Therapeutics Limited Fundamentals Summary
| PTX fundamental statistics | |
|---|---|
| Market cap | AU$33.82m |
| Earnings (TTM) | -AU$8.24m |
| Revenue (TTM) | AU$3.71m |
9.1x
P/S Ratio-4.1x
P/E RatioIs PTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PTX income statement (TTM) | |
|---|---|
| Revenue | AU$3.71m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$3.71m |
| Other Expenses | AU$11.95m |
| Earnings | -AU$8.24m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.01 |
| Gross Margin | 100.00% |
| Net Profit Margin | -221.91% |
| Debt/Equity Ratio | 1.8% |
How did PTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 01:00 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Prescient Therapeutics Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Paul Hickman | Edison Investment Research |
| Joseph Pantginis | H.C. Wainwright & Co. |